fbpx

Category

Lundbeckfonden Emerge
– Data to be Presented at the ESMO Virtual Congress 2020 – Melanoma trial (MM1636) shows best-in-class efficacy data in first line melanoma of IO102 and IO103 in combination with nivolumab (anti-PD1 antibody) Copenhagen, Denmark – September 18, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology,...
Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, into clinical trials as a novel treatment for the symptoms of myasthenia...
SAN DIEGO and COPENHAGEN, April 22, 2020 /PRNewswire/ — AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin® Clobetasol patch (“Rivelin-CLO”) met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus (“OLP”). In the largest randomized, double-blind, placebo-controlled...
Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark – February 25, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of...
SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus (VLS), a painful genital skin condition that affects up to 3% of post-menopausal women....
In April, US investors have the opportunity to meet with 23 Danish biotech startups in New York during DKBIO 2019. Denmark already today has a thriving biotech and pharma industry fuelled by a strong academic environment, talent pool and capital. DKBIO conference on 10 and 11 April in New York provides a platform for US...
SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge (Copenhagen) and LSP (Amsterdam), together with North-East Family Office (Copenhagen) and Wellington Partners (Munich). SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and...
Andreas Jurgeit is to join Lundbeckfonden Emerge, the early stage investment unit of the Lundbeck Foundation, as a partner on 1 January 2019. Andreas has been active in various operational and financing roles over the last decade. He was first exposed to biotech as a scientist collaborating with 3V Biosciences during his PhD and later...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ — Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a Phase 2b clinical trial of Rivelin® Clobetasol patch (Rivelin®-CLO) for oral lichen planus (OLP). Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol...
1 2

News

DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge